EUCTR2020-003313-35-AT进行中（未招募）1 期
A Phase 2, Randomized, Double-blind, Placebo-controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Dicerna Pharmaceuticals, Inc., a wholly owned subsidiary of Novo Nordisk0 个研究点目标入组 46 人开始时间: 2022年1月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age 18 to 75 years, inclusive, at the time of signing the ICF.
- •2. Documented diagnosis of PiZZ-type AATD, confirmed by genotyping. Historical genotyping data may be used, if available.
- •3. AATLD, with a liver fibrosis score categorized as F1, F2, F3, or F4 in the METAVIR scoring system, documented by liver biopsy during Screening.
- •4. Post-bronchodilator FEV1 > 45% of predicted at Screening.
- •5. Participants receiving augmentation therapy during the study are eligible to participate.
- •6. eGFR at Screening = 60 mL/min normalized to 1.73 m2 BSA.
- •7. Non-smokers (defined as having not smoked cigarettes daily for at least the preceding 12 months) with current non-smoking status confirmed by urine cotinine at Screening AND any previous smoking history prior to 12 months must be < 15 pack years, including use of e-cigarettes. Participants may be on nicotine replacement (patch or gum). A positive urine cotinine result due to nicotine replacement is acceptable for enrollment at the discretion of the Investigator.
- •8. Male or female
- •Male participants:
- •A male participant with a partner of childbearing potential must agree to use contraception, as detailed in Section 10.4.2, during the treatment period and for at least 12 weeks after the last dose of study intervention and refrain from donating sperm during this period. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- •Female participants:
- •A female participant is eligible to participate if she is not pregnant (see Section 10.4.3) and not breastfeeding. WOCBP must be using a highly effective method of contraception, as defined in Section 10.4.2.
- •9. Capable of giving signed informed consent, which includes compliance with the requirements (including consent to undergo paired liver biopsies) and restrictions listed in the ICF and in this protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 41
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1. Any condition which, in the investigator's opinion might jeopardize participant's safety or compliance with the protocol.
- •2. History of chronic liver disease other than non-alcoholic fatty liver disease from any cause other than PiZZ-type AATD. Diagnostic testing exclusions are defined in the Diagnostic Assessments section below.
- •3. Child-Pugh Score B or C
- •4. History of one single severe exacerbation of underlying lung disease in the year prior to randomization. A severe exacerbation is defined as an exacerbation that requires hospitalization or a visit to the emergency room.
- •5. History of rapid decline in pulmonary function, as assessed by the Investigator.
- •6. Known or suspected abuse of drugs in the opinion of the Investigator
- •7. Known or suspected excessive consumption of alcohol ( = 21 units of alcohol per week in men and = 14 units of alcohol per week in women; where a unit of alcohol is equivalent to a 12-ounce beer, 4-ounce glass of wine, or 1 ounce shot of hard liquor as defined by the World Health Organization)
- •8. Any of the following: myocardial infarction, stroke, classification of heart failure New York Heart Association (NYHA) Class IV, hospitalization for unstable angina pectoris or transient ischaemic attack within the past 90 days prior to the day of screening (V2A) and between screening and randomization
- •9. History of malignancy, unless the malignancy (other than hepatocellular or lung cancer) has been in complete remission off chemotherapy and without additional medical or surgical interventions within the preceding 5 years, or unless the malignancy has been an adequately treated skin cancer (other than melanoma) or, superficial bladder tumor, or in situ cervical cancer in the preceding 1 year.
- •10. Use of an RNAi drug at any time
- •11. History of one or more of the following reactions to an oligonucleotide-based therapy:
- •a. Severe thrombocytopenia (platelet count < 100,000/ mm^3)
- •b. hepatotoxicity, defined as ALT or AST > 3 × ULN and total bilirubin > 2 × ULN or INR > 1.5
- •c. severe flu-like symptoms leading to discontinuation of therapy
- •d. localized skin reaction from the injection (graded severe) leading to discontinuation of therapy
- •e. coagulopathy/clinically significant prolongation of clotting time
- •12. Participation in any clinical study in which they received an IMP within 4 months (or 5 times the half-life, whichever is longer) before Screening
- •13. AST and ALT > 5 × ULN at Screening. For individuals with any serum aminotransferase elevation > 2 × ULN, autoimmune hepatitis should be ruled out through the appropriate screening tests, which may include total IgG or gamma-globulin levels and/or serologic markers (i.e., antinuclear antibodies, anti-smooth-muscle antibodies at a titer of at least 1:40, anti-liver/kidney microsomal-1 antibodies, antiliver cytosol antibody [anti-LC 1], or antisoluble liver/liver pancreas [anti-SLA/LP] antibodies).
- •14. ALP 2 × ULN at Screening
- •15. Serum AFP value > 100 ng/mL at Screening. If AFP at screening is > ULN but < 100 ng/mL, the participant is still eligible if an appropriate hepatic imaging study reveals no lesions
- •16. Positive screening for antimitochondrial antibodies (only required if primary biliary cirrhosis is suspected)
- •17. Platelets < 100,000/mm 3 at Screening
- •18. INR > 1.6 × ULN at Screening
- •19. Positive screening for HBsAg, HCV antibodies, or HIV1 and 2 antibodies. If a participant has been tested in the past 3 months,
- •medical record documentation of this testing
研究者
相似试验
进行中（未招募）
不适用
A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial CystitisBladder Pain Syndrome / Interstitial CystitisMedDRA version: 14.1Level: LLTClassification code 10071166Term: Bladder pain syndromeSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.1Level: LLTClassification code 10008928Term: Chronic interstitial cystitis NOSSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.1Level: LLTClassification code 10008927Term: Chronic interstitial cystitisSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.1Level: PTClassification code 10011796Term: Cystitis interstitialSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2011-004555-39-NLAstellas Pharma Europe B.V.300
进行中（未招募）
1 期
A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A InfectioEUCTR2015-003002-17-BEJanssen-Cilag International NV90
进行中（未招募）
1 期
A study to investigate how safe and able to produce an effect in the body study drug VX-150 is in patients with pain that typically begins in the feet or handPain Caused by Small Fiber NeuropathyMedDRA version: 20.0Level: PTClassification code 10033371Term: PainSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 20.1Level: PTClassification code 10073928Term: Small fibre neuropathySystem Organ Class: 10029205 - Nervous system disordersEUCTR2017-001042-10-ITVERTEX PHARMACEUTICALS INCORPORATED89
进行中（未招募）
1 期
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial HypertensioEUCTR2008-007455-26-BEGilead Sciences, Inc.160
尚未招募
2 期
A study to calculate efficacy and safety of SAR441566 in adults with rheumatoid arthritisCTRI/2024/05/067017Sanofi Healthcare India Pvt Limited (SHIPL)